Alopecia

Latest News

Psychosocial Impact of Alopecia Areata on Pediatric and Adolescent Patients
Psychosocial Impact of Alopecia Areata on Pediatric and Adolescent Patients

October 9th 2024

A recent review found hair loss can severely impact self-esteem and body image, leading to social anxiety and emotional distress among affected youth.

Thyroid Disorders and Their Link to Alopecia Areata
Thyroid Disorders and Their Link to Alopecia Areata

October 3rd 2024

Addressing Causes of Female Hair Loss and Exploring Preventative Measures
Addressing Causes of Female Hair Loss and Exploring Preventative Measures

October 3rd 2024

Deuruxolitinib Shows Efficacy in Hair Regrowth, Patient Satisfaction, and Psychosocial Wellbeing in Severe Alopecia Areata
Deuruxolitinib Shows Efficacy in Hair Regrowth, Patient Satisfaction, and Psychosocial Wellbeing in Severe Alopecia Areata

September 27th 2024

How Managing Comorbidities Can Transform Alopecia Areata Treatment Outcomes
How Managing Comorbidities Can Transform Alopecia Areata Treatment Outcomes

September 23rd 2024

More News

Poster Presentations Demonstrate Efficacy of Deuruxolitinib in Patients With Moderate to Severe Alopecia Areata

Poster Presentations Demonstrate Efficacy of Deuruxolitinib in Patients With Moderate to Severe Alopecia Areata

Cameron Santoro
March 18th 2024

The data suggests that the medication, which targets specific cellular pathways, promotes hair regrowth in AA with minimal adverse effects.

What’s New in Hair Loss Therapies and Exosomes?

What’s New in Hair Loss Therapies and Exosomes?

Kaitlyn Bader, Senior Editor ;Ronda Farah, MD
March 12th 2024

Ronda Farah, MD, FAAD, reviews top hair loss pearls from her 5 sessions at AAD 2024.

Pointers With Portela: Hair Loss Q&A

Pointers With Portela: Hair Loss Q&A

Dustin Portela, DO
March 6th 2024

In this week’s Pointers With Portela, the 208SkinDoc answers common hair loss questions.

Nektar Announces Initiation of Phase 2b Study for Rezpegaldesleukin in Severe, Very Severe Alopecia

Nektar Announces Initiation of Phase 2b Study for Rezpegaldesleukin in Severe, Very Severe Alopecia

Emma Andrus, Associate Editor
March 5th 2024

The study will evaluate rezpegaldesleukin and its effect on Severity of Alopecia Tool scoring by the conclusion of a 36-week period.

Experts Review Key Factors in Alopecia Areata Severity and Morbidity Index, Treatment Decisions

Experts Review Key Factors in Alopecia Areata Severity and Morbidity Index, Treatment Decisions

Cameron Santoro
March 4th 2024

Factors including disease duration, treatment response, and mental health were listed as crucial factors in severity and treatment.

<12
© 2024 MJH Life Sciences

All rights reserved.